Results 1 to 10 of about 194,103 (135)

Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review [PDF]

open access: yesFrontiers in Oncology, 2021
Background and Aims: This study aimed at comparing the efficacy and safety of eltrombopag (EPAG) plus immunosuppressive therapies (ISTs) and haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the frontline treatment for severe ...
Yuan Yang   +3 more
doaj   +2 more sources

BK polyomavirus-associated nephropathy [PDF]

open access: yesChildhood Kidney Diseases, 2022
BK polyomavirus (BKPyV) is a ubiquitous virus residing in the kidney tubules and is clinically significant only in immunocompromised patients. In clinical practice, BKPyV is a causative pathogen of BKPyV-associated nephropathy (BKVAN) in kidney allograft
Yo Han Ahn, Hee Gyung Kang
doaj   +1 more source

Dialysis Dependency at Discharge in De Novo ANCA Associated Renal Limited Vasculitis: Should We Avoid Further Immunosuppression?

open access: yesRevista Portuguesa de Nefrologia e Hipertensão, 2022
Introduction: ANCA associated vasculitis commonly affects the kidneys. The intense inflammatory damage disrupts the glomerular architecture. Induction immunosuppressive therapy is responsible for a large part of the morbidity and mortality of these ...
Rui Filipe Nogueira   +4 more
doaj   +1 more source

Autoimmune encephalitis and epilepsy: evolving definition and clinical spectrum [PDF]

open access: yesClinical and Experimental Pediatrics, 2020
Advances in autoimmune encephalitis studies in the past 10 years have led to the identification of new syndromes and biomarkers that have transformed the diagnostic approach to the disorder.
Joo Hee Seo   +5 more
doaj   +1 more source

Impact of B Cell Depletion on COVID-19 in Kidney Transplant Recipients

open access: yesViruses, 2023
Kidney transplant recipients are patients at high risk for coronavirus disease 2019 (COVID-19) due to being on immunosuppressive therapy. B cell depletion therapy, including rituximab, is an important strategy for ABO-incompatible transplants.
Naohiro Aida   +7 more
doaj   +1 more source

Monoclonal antibody‐mediated immunosuppression enables long‐term survival of transplanted human neural stem cells in mouse brain

open access: yesClinical and Translational Medicine, 2022
Background As the field of stem cell therapy advances, it is important to develop reliable methods to overcome host immune responses in animal models. This ensures survival of transplanted human stem cell grafts and enables predictive efficacy testing ...
Lisa M. McGinley   +9 more
doaj   +1 more source

Impact of COVID-19 on patients treated with autologous hematopoietic stem cell transplantation: A retrospective cohort study

open access: yesUpsala Journal of Medical Sciences, 2022
Objective: To describe how coronavirus disease 2019 (COVID-19) affects patients with hematological malignancies treated with autologous hematopoietic stem cell transplantation (ASCT).
Thomas Silfverberg   +3 more
doaj   +1 more source

Immunosuppressive Drug Therapy [PDF]

open access: yesCold Spring Harbor Perspectives in Medicine, 2013
The first successful kidney transplantation between monozygotic identical twins did not require any immunosuppressive drugs. Clinical application of azathioprine and glucocorticosteroids allowed the transfer of organs between genetically disparate donors and recipients.
Choli, Hartono   +2 more
openaire   +2 more sources

Reactivation of Tumor-like Chagas Disease in the Central Nervous System in Cardiac Transplant Patients: A Case Series and Literature Review

open access: yesBrazilian Neurosurgery, 2023
Introduction Chagas disease is an important public health problem in Latin American countries, affecting ∼ 6 million people within the region.
Antônio Gilson Prates Júnior   +6 more
doaj   +1 more source

Preventing kidney transplant failure by screening for antibodies against human leucocyte antigens followed by optimised immunosuppression: OuTSMART RCT

open access: yesEfficacy and Mechanism Evaluation, 2023
Design Investigator-led, prospective, open-labelled marker-based strategy (hybrid) randomised trial. Background Allografts in 3% of kidney transplant patients fail annually.
Stringer Dominic   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy